Ir al contenido
The information contained in this website is intended for International Health Care Professionals. Patients, please refer to your physician for information.
  • About Us
    • Brand History
    • History of P4HB
  • What is GalaFLEX?
    • Instructions for Use
    • What is P4HB?
    • Properties
    • The Scaffold Collection
      • GalaFLEX®
      • GalaFLEX 3D TM
      • GalaFLEX 3DR TM
    • Information for your patient
  • Publications
  • Contact Us
    • Locations
Menú
  • About Us
    • Brand History
    • History of P4HB
  • What is GalaFLEX?
    • Instructions for Use
    • What is P4HB?
    • Properties
    • The Scaffold Collection
      • GalaFLEX®
      • GalaFLEX 3D TM
      • GalaFLEX 3DR TM
    • Information for your patient
  • Publications
  • Contact Us
    • Locations
The information contained in this website is intended for International Health Care Professionals. Patients, please refer to your physician for information.

Publications

Prospective evaluation of poly-4-hydroxybutyrate mesh in CDC class I/high-risk ventral and incisional hernia repair: 18-month follow-up.

John Scott Roth, Gary J. Anthone, Don J. Selzer, Benjamin K. Poulose, James G. Bittner, William W. Hope, Raymond M. Dunn, Robert G. Martindale, Matthew I. Goldblatt, David B. Earle, John. R. Romanelli, Gregory J. Mancini, Jacob A. Greenberg, John G. Linn, Eduardo Parra-Davila

Surgical Endoscopy Volume 32, Issue 4, pp 1929–1936

April 2018

Full article : https://www.ncbi.nlm.nih.gov/pubmed/29063307

Abstract

Background:

Long-term resorbable mesh represents a promising technology for complex ventral and incisional hernia repair (VIHR). Preclinical studies indicate that poly-4-hydroxybutyrate (P4HB) resorbable mesh supports strength restoration of the abdominal wall. This study evaluated outcomes of high-risk subjects undergoing VIHR with P4HB mesh.

Methods:

This was a prospective, multi-institutional study of subjects undergoing retrorectus or onlay VIHR. Inclusion criteria were CDC Class I, defect 10-350 cm2, ≤ 3 prior repairs, and ≥ 1 high-risk criteria (obesity (BMI: 30-40 kg/m2), active smoker, COPD, diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, hypoalbuminemia, advanced age, and renal insufficiency). Physical exam and/or quality of life surveys were performed at regular intervals through 18 months (to date) with longer-term, 36-month follow-up ongoing.

Results:

One hundred and twenty-one subjects (46M, 75F) with an age of 54.7 ± 12.0 years and BMI of 32.2 ± 4.5 kg/m2 (mean ± SD), underwent VIHR. Comorbidities included the following: obesity (n = 95, 78.5%), hypertension (n = 72, 59.5%), cardiovascular disease (n = 42, 34.7%), diabetes (n = 40, 33.1%), COPD (n = 34, 28.1%), malignancy (n = 30, 24.8%), active smoker (n = 28, 23.1%), immunosuppression (n = 10, 8.3%), chronic corticosteroid use (n = 6, 5.0%), advanced age (n = 6, 5.0%), hypoalbuminemia (n = 3, 2.5%), and renal insufficiency (n = 1, 0.8%). Hernia types included the following: primary ventral (n = 17, 14%), primary incisional (n = 54, 45%), recurrent ventral (n = 15, 12%), and recurrent incisional hernia (n = 35, 29%). Defect and mesh size were 115.7 ± 80.6 and 580.9 ± 216.1 cm2 (mean ± SD), respectively. Repair types included the following: retrorectus (n = 43, 36%), retrorectus with additional myofascial release (n = 45, 37%), onlay (n = 24, 20%), and onlay with additional myofascial release (n = 8, 7%). 95 (79%) subjects completed 18-month follow-up to date. Postoperative wound infection, seroma requiring intervention, and hernia recurrence occurred in 11 (9%), 7 (6%), and 11 (9%) subjects, respectively.

Conclusions:

High-risk VIHR with P4HB mesh demonstrated positive outcomes and low incidence of hernia recurrence at 18 months. Longer-term 36-month follow-up is ongoing.

This study was sponsored by C. R. Bard, Inc. (Davol), Warwick, RI.

Disclosures

Authors were reimbursed for expenses related to the conduct of the study. JSR, GJA, JGB, WWH, RGM, MIG, DBE, GJM, JAG, EPD, BJS, CRD, and GRV are paid consultants for C. R. Bard, Inc. (Davol). Poulose conflicts: Bard-Davol-research (pertains to this study); Americas Hernia Society Quality Collaborative-compensation; Ariste Medical-consulting; Pfizer-consulting. Deeken conflicts: Covalent Bio, LLC – Owner and Principal Consultant; Biom’Up – consulting; Colorado Therapeutics – consulting; C. R. Bard/Davol, Inc. – consulting (pertains to this study); Musculoskeletal Transplant Foundation – paid Grant reviewer; Johnson & Johnson Medical GmbH – consulting; TELA Bio, Inc. – consulting.

  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact
Menú
  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact

See instructions for use here

+ Show References
+ Show patents
Twitter Instagram Linkedin Facebook
Galatea Surgical© 2023. All Rights reserved 500075 Rev B
  • Terms of Use
  • Privacy Policy
Menú
  • Terms of Use
  • Privacy Policy
+ Show References
+ Show patents
Twitter Instagram Linkedin Facebook
Galatea Surgical© 2023. All Rights reserved 500075 Rev DB
  • Terms of Use
  • Privacy Policy
  • Terms of Use
  • Privacy Policy
Important Cookie Information – This message will only appear once. Galatea Surgical website uses cookies. By continuing to browse the site, you are agreeing to the use of cookies.
Read Privacy Policy ACCEPT
Manage consent

Privacy Overview

Read Privacy Policy

Necessary
Siempre activado
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
GUARDAR Y ACEPTAR
The information contained in this website is intended for International Health Care Professionals. Patients, please refer to your physician for information.
  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact
  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact